December 16, 2010

Evolva initiates multiple ascending dose study with EV-077

Evolva Holding SA (SIX: EVE), today announced it has initiated a multiple ascending dose Phase I clinical study with an extended release oral formulation of EV-077.
PDF Download English Version

read more »

December 16, 2010

ImVisioN Therapeutics enters strategic partnership with IDT Biologika

ImVisioN Therapeutics AG, a biopharmaceutical company pioneering intralymphatic immunotherapy (ILIT™), today announced that it has entered a strategic partnership with IDT Biologika, a globally-integrated contract manufacturer of vaccines and biopharmaceuticals.
PDF Download

read more »

December 13, 2010

Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma

Anaphore Inc. today announced that the company has entered into a partnership with Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) for the research,  development and commercialization of novel protein therapies for autoimmune disease. The partnership will be based on Anaphore’s proprietary platform technology.
PDF Download

read more »

December 07, 2010

Data for ENMD-2076 Phase 1 studies in multiple Myeloma and Leukemia presented at ASH

EntreMed, Inc. (Nasdaq: ENMD), today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology (ASH) Annual Meeting being held December 4-7 in Orlando, Florida. The ongoing multi-center Phase 2 study with ENMD-2076 in ovarian cancer patients is progressing as planned.
PDF Download

read more »

December 06, 2010

S*BIO’s Novel JAK2 Inhibitor SB1518 Is Shown to Be a Safe and Effective Therapy in Phase 1/2 Studies For Patients with Symptomatic Myelofibrosis and Relapsed/Refractory Lymphoma

S*BIO Pte Ltd today announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens. SB1518 was also well tolerated in patients with relapsed/refractory lymphoma. Results were presented at the 52nd ASH Annual Meeting and Exposition in Orlando, Fla.
PDF Download

read more »

December 01, 2010

Ground breaking data on Synosia’s investigational new Parkinson’s drug published in The Journal of Neuroscience

 New data on Synosia Therapeutics’ investigational drug SYN-115 were published today in The Journal of Neuroscience1. The data obtained using perfusion magnetic resonance imaging (MRI) in patients with Parkinson’s disease show that SYN-115 crosses the blood-brain barrier to affect areas of the brain linked to the disease in a dose-dependent manner.
PDF Download

read more »

October 18, 2010

S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)

S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
PDF Download

read more »

October 12, 2010

UCB and Synosia Therapeutics sign strategic alliance in neurology

UCB and Synosia Therapeutics announced today a new strategic partnership in neurology. Synosia has granted UCB a license for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications. Both are in Phase II clinical development for the treatment of Parkinson's disease.
PDF Download

read more »

October 07, 2010

Symetis closes CHF 25 million financing led by Endeavour Vision and NBGI Ventures, Eric Milledge appointed Chairman of the Board

Lausanne, Switzerland — 7 October 2010 – Symetis SA, a private Swiss company developing new transcatheter aortic valve implantation (TAVI) systems, announced today that it has raised CHF 25 million in a new financing round co-led by Endeavour Vision and NBGI Ventures. Existing investors Truffle Capital, Novartis Venture Fund, Wellington Partners, Vinci Capital – Renaissance PME, Banexi Ventures and BiomedInvest also participated.
PDF Download

read more »

September 23, 2010

S*BIO Announces US$5 Million Investment by Mitsui Ventures

S*BIO Pte Ltd today announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO’s clinical programs.
PDF Download

read more »

September 23, 2010

Symetis reports on its trans-apical ACURATE TA™ first-in-man clinical study: - 40 patients enrolment completion; positive preliminary results

Symetis SA, a private Swiss company developing new transcatheter aortic valve implantation (TAVI) systems, announced today the completion of patient enrolment in its ACURATE TA™ first-in-man (FIM) clinical study and positive preliminary results. ACURATE TA™ is a self-aligning nitinol stent valve designed for optimal trans-apical delivery, providing the physician with unmatched positioning tolerance and ease of use.
PDF Download

read more »

July 26, 2010

NovImmune enters exclusive antibody licensing agreement with Genentech

NovImmune, an antibody-focused research and development biotech company, announced today that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies.
PDF Download

read more »

June 30, 2010

Aravis Energy in the Swiss Press - Handelszeitung, 30 June 2010

Click here to read the article.

read more »

June 29, 2010

OMEROS Successfully unlocks Orphan GPCRS

Omeros Corporation (NASDAQ: OMER) today announced that it has successfully identified compounds that interact with three orphan G protein-coupled receptors (GPCRs) linked to cancer, metabolic disorders and appetite control. This breakthrough demonstrates Omeros’ unique capability to introduce a large number of new drug targets to the pharmaceutical industry, which could lead to the development of novel therapeutics across a wide range of diseases and disorders. GPCRs represent the premier family of drug targets, with more than 30 percent of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros expects to unlock a large percentage of these for drug development.
PDF Download

read more »

June 14, 2010

Evolva Article in Roche Magazine RoSearch April 2010

Click here to read the article.

read more »

June 09, 2010

S*BIO Completes Enrollment of Patients in Phase 2 Clinical Trials for its JAK2 Inhibitor

S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF).
PDF Download

read more »

May 13, 2010

Initial public offering of shares of common stock of Ikaria, Inc

Click here to read the artilce

read more »

May 04, 2010

Aravis sells wind farm to Swiss utility company EBM

Aravis Energy I LP (Aravis Energy), a Swiss venture capital firm based in Zurich, has sold the Swiss wind energy company LuciaWind AG to the utility company EBM, which is based in Münchenstein in the canton of Baselland. LuciaWind AG operates a 42-megawatt wind farm in Spain. The farm, which has 14 3-megawatt wind turbines, supplies electricity for over 22,000 Swiss households and thus avoids 86,000 tonnes of CO2 emissions per year. The wind farm is situated in Andalusia on Spain’s Atlantic coast and is one of the projects in Aravis Energy’s portfolio. Aravis Energy is the first Swiss venture capital firm to focus on the development and realisation of projects in the renewable energies sector. The purchase of the wind farm makes EBM one of the largest Swiss wind farm owners. The investment volume is over 100 million Swiss francs.
PDF Download English Version
PDF Download German Version
PDF Download French Version

read more »

May 04, 2010

Evolva announces Board nominations

Evolva Holding SA (SIX: EVE) is pleased to announce the nomination of Sir Tom McKillop, Claus Braestrup and Nicole Dubois for election to its Board of Directors. The three candidates will be proposed for election in the Annual General Meeting (AGM), to be held on 10 June 2010. Registered shareholders will receive the invitation to the AGM in May.
PDF Download

read more »

May 04, 2010

S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO’s novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.
PDF Download

read more »

May 03, 2010

Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery

Omeros Corporation (Nasdaq: OMER) today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical benefits.
OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative joint function and motion and reduce postoperative pain. Omeros plans to present these additional data tomorrow in its webcast presentation at the Deutsche Bank Health Care Conference at 2:50 p.m. EDT and, for those not attending, has provided the clinical trial results below.
PDF Download

read more »

April 14, 2010

Synosia Therapeutics’ SYN-115 Improves Motor and Non-Motor Function in Patients with Mild- to-Moderate Parkinson’s Disease

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company’s adenosine 2a (A2a) receptor antagonist (SYN-115) in Parkinson’s disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson’s disease (PD) either alone or in combination with levodopa. The results also clearly illustrate the value of perfusion magnetic resonance imaging (MRI) as a tool to rapidly evaluate the pharmacodynamic effects of new drugs in the brain. Findings will be presented today at the American Academy of Neurology 62nd Annual Meeting in Toronto, Ontario, Canada.
PDF Download

read more »

April 09, 2010

Erste Offshore-Fonds Repatriierung einer Risikokapital Gesellschaft mit „Limited Partnership“-Struktur von der FINMA bewilligt

Aravis Biotech II General Partner AG gibt bekannt, dass sie als erste Management Gesellschaft der Schweiz eine bestehende „Limited Partnership“ Gesellschaft nach Cayman Island Recht erfolgreich in die Schweiz repatriiert hat. Die Aravis Biotech II LP, Kommanditgesellschaft für kollektive Kapitalanlage1 untersteht seit dem 1. April 2010 der Aufsicht der FINMA als geschlossene kollektive Kapitalanlage.
PDF Download

read more »

March 31, 2010

Omeros Reports Phase 2 Data Showing Multiple Clinical Benefits in Patients Undergoing Arthroscopic Meniscectomy Surgery

Omeros Corporation (Nasdaq: OMER) today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy,
demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits. OMS103HP is an investigational drug product that is added to arthroscopic irrigation solution and is designed to improve postoperative joint function and motion and reduce postoperative pain.
PDF Download

read more »

March 30, 2010

IKARIA® ACQUIRES NEW DRUG APPLICATION FOR LUCASSIN®

Ikaria Holdings, Inc. announced today that it has acquired the New Drug Application (NDA) and the Investigational New Drug (IND) application, to LUCASSIN® (terlipressin for injection) from Orphan Therapeutics, assuming all future development and ownership of the drug in North America and Australia. LUCASSIN is being
developed for the treatment of hepatorenal syndrome (HRS) Type 1, an orphan-designated condition for which there currently are no approved drugs in the U.S.
PDF Download

read more »

March 11, 2010

Evolva participates in food ingredient research initiative

Evolva Holding SA (SIX: EVE) today announced that its Danish subsidiary has commenced a research initiative focusing on novel ways to produce vanillin and arabinogalactan proteins. Together with Evolva, the initiative includes four leading Danish research groups from the University of Copenhagen and the Danish Technical University, Danisco, and the Lawrence Berkeley National Laboratory, a major US research institution.
PDF Download

read more »

March 09, 2010

Omeros Licenses PDE7 Compounds for Parkinson's Disease Program

Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders. Omeros has demonstrated a previously unknown link between phosphodiesterase-7 (PDE7) and movement disorders such as Parkinson's disease and Restless Legs Syndrome. The agreement with Asubio gives Omeros an expedited path to the clinic by providing advanced preclinical product candidates that are ready for additional toxicology studies in preparation for a Phase 1 clinical trial.
PDF Download

read more »

February 01, 2010

Synosia Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson’s Disease

Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.
PDF Download

read more »

January 04, 2010

Evolva enters discovery collaboration with Roche

Evolva Holding SA (SIX: EVE) today announced that it has signed an agreement with Roche (SIX: ROG, RO; OTCQX: RHHBY) to create compounds with activity on targets in oncology and anti-infectives using Evolva’s technology platform.
PDF Download

read more »